Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Organovo (NASDAQ:ONVO) in a research report report published on Tuesday morning. The firm issued a sell rating on the medical research company’s stock.

Organovo Price Performance

ONVO opened at $0.40 on Tuesday. The firm has a market capitalization of $6.87 million, a price-to-earnings ratio of -0.47 and a beta of 0.45. The company’s 50 day simple moving average is $0.44 and its two-hundred day simple moving average is $0.45. Organovo has a 1-year low of $0.32 and a 1-year high of $1.83.

Organovo (NASDAQ:ONVO) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.02. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.05 million. Organovo had a negative return on equity of 346.26% and a negative net margin of 10,151.64%. On average, equities analysts anticipate that Organovo will post -0.77 earnings per share for the current fiscal year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.